Drawing for MYRIAD ONCOLOGY

USPTO serial 99976312

MYRIAD ONCOLOGY

Reviewed by CopyMark Law Group

Status 819
Filing date
Status date
Registration date
—
Examiner
CHOE, JULIE H
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MYRIAD ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joyce M. Ferraro

Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
010Medical test kit related to oncology comprising specimen collection containers in the nature of tubes for the collection of bodily fluids containing cell-free DNA, printed instructions and test forms, materials for transmitting specimens in the nature of envelopes, cardboard boxes, and plastic bags all in the medical field, and printed user information inserts being formsACTIVEFeb 11, 2026
044Medical testing services related to oncology; genetic and genomic testing related to oncology for medical purposes; genetic testing for medical purposes; genetic testing services for diagnostic or treatment purposes; genetic counseling; medical diagnostic testing, monitoring, and reporting services; providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing for the detection of cancer to assess the presence or absence of residual disease; health assessment services; providing personalized healthcare and medical information, namely, providing medical information and reports; providing medical information, consultancy and advisory services; health evaluation services, namely, performing health assessments and health screening for purposes of determining medical risks and further testingACTIVEMay 1, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Nov 17, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Nov 16, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Nov 16, 2026DPCCDIVISIONAL PROCESSING COMPLETE—
Nov 16, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 16, 2026IUAFUSE AMENDMENT FILED—
Sep 16, 2026DRRRDIVISIONAL REQUEST RECEIVED—
Sep 16, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2026ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Sep 16, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
May 26, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 26, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 26, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 26, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 26, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 17, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 20, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 20, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 14, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 19, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 19, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 19, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2025ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Oct 9, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Oct 9, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 9, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 24, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 24, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 24, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 25, 2025GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jun 25, 2025GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jun 25, 2025CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jun 24, 2025DOCKASSIGNED TO EXAMINER—
Mar 6, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 6, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 6, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance